Breast cancer
Acute skin toxicity comparison of adjuvant two-weekly versus three-weekly radiotherapy in breast cancer
Who can joinAdults
Age18+ years
Kind of studyPhase 2: does it work?
What it testsA medicine and radiation and surgery or a procedure
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
JIPMERPuducherry, PuducherryDirections ↗
Registry summary (technical)
Acute skin toxicity comparison of adjuvant two-weekly accelerated hypofractionated versus three-weekly moderately hypofractionated radiotherapy in breast cancer- A Phase 2, open label, randomized control trial - nil
Sponsor: JIPMER
CTRI/2024/10/074718 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 22 Jun 2026 · read by us 5 Nov 2026